Orchestra BioMed Holdings, Inc.
Price Action
Technical Summary
CONSOLIDATINGOrchestra BioMed Holdings, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 61), indicating performance broadly in line with the market. Earnings contraction of 10% provides fundamental context to the price action. Investors should exercise caution due to high volatility (71% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.02 | +18.26% | ABOVE |
| 50 SMA | $4.03 | +17.78% | ABOVE |
| 100 SMA | $4.16 | +14.17% | ABOVE |
| 150 SMA | $4.24 | +11.98% | ABOVE |
| 200 SMA | $4.01 | +18.47% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is OBIO in an uptrend right now?
OBIO has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is OBIO overbought or oversold?
OBIO's RSI (14) is 59. The stock is in neutral territory, neither overbought nor oversold.
Is OBIO outperforming the market?
OBIO has a Relative Strength (RS) Rating of 61 out of 99. OBIO is performing about average compared to the market.
Where is OBIO in its 52-week range?
OBIO is trading at $4.75, which is 88% of its 52-week high ($5.42) and 79% above its 52-week low ($2.20).
How volatile is OBIO?
OBIO has a Beta of 1.83 and 52-week volatility of 71%. It's more volatile than the S&P 500 - expect bigger swings.